Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands

Eli Lilly (LLY) and AbbVie (ABBV) are receiving elevated price targets from Wall Street analysts following expanded Medicare coverage for their obesity medications. The Medicare GLP-1 Bridge program represents a material expansion of addressable market, directly removing a key reimbursement barrier that previously constrained growth trajectories for both Zepbound (semaglutide) and Foundayo (tirzepatide oral formulation).

The analyst upgrades reflect confidence in revenue acceleration and market penetration across the obesity therapeutic class. This policy shift signals sustained institutional momentum behind GLP-1 adoption, particularly among seniors—a demographic with substantial prevalence of obesity-related comorbidities. The broadened access reduces formulary friction and out-of-pocket costs, mechanics that historically throttle pharmaceutical adoption rates.

For LLY, the oral formulation advantage in Foundayo positions the company for differentiation versus existing injectable therapies. AbbVie's positioning, while reliant on partner distribution, benefits from category tailwinds and expanded reimbursement infrastructure. Both names face execution risk on manufacturing scale and market share competition within an increasingly crowded GLP-1 landscape.

Sector implication: This development reinforces Health Care as a defensive growth sector with pricing power and structural demand drivers. Medicare policy expansion validates the obesity treatment category as a multi-billion-dollar enduring opportunity, benefiting integrated pharmaceutical platforms with diversified GLP-1 portfolios.